Literature DB >> 19455356

Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy.

Giampaolo Talamo1, Jason Liao, Michael G Bayerl, David F Claxton, Maurizio Zangari.   

Abstract

AIMS: Medical literature provides only scarce data about the degree of pain experienced by patients undergoing a bone marrow aspiration and biopsy (BMAB), and little is known about the factors that can modify the perception of pain. In this study, we evaluated the effectiveness of a combination of analgesia and anxiolysis in reducing the pain score of patients undergoing BMAB.
MATERIALS AND METHODS: Eighty-four consecutive adult patients underwent BMAB after local anesthesia with 5 mL of lidocaine hydrochloride 1% aqueous solution in the left posterior superior iliac crest. Analgesia was obtained with acetaminophen 650 mg and oxycodone 10 mg, and anxiolysis was obtained with lorazepam 2 mg, all drugs given once orally 30 min before the procedure. We assessed the pain level with the Wong-Baker Faces Pain Rating Scale, which distinguishes six levels of pain, from 0 to 5.
RESULTS: The 34 patients who received an oral administration of analgesia and anxiolysis reported pain at lower levels, i.e., in the range of 0-2, more frequently than the 50 patients who underwent BMAB without analgesia/anxiolysis (78% vs 64%, respectively). Among several predictors analyzed using a multivariate regression model, three were found to be associated with decreased pain level: the use of analgesia/anxiolysis, male sex, and increase in age (all with p values <0.05). Length of the extracted bone specimen, body mass index, and need of a spinal needle for anesthesia in obese patients did not predict for pain level.
CONCLUSIONS: An oral administration of prophylactic regimen of analgesia and anxiolysis, at the above-mentioned doses, produced a statistically significant reduction of the perception of pain in patients undergoing BMAB, but its effect did not seem to provide a major and clinically significant reduction of pain level.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455356     DOI: 10.1007/s00520-009-0652-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  10 in total

Review 1.  Bone marrow aspiration.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

2.  Bone marrow biopsy symptom control and palliative care consultation.

Authors:  Charles F von Gunten; Matthew Soskins
Journal:  J Pain Symptom Manage       Date:  2007-03       Impact factor: 3.612

Review 3.  [Local anesthetics--maximum recommended doses].

Authors:  H C Niesel
Journal:  Anaesthesiol Reanim       Date:  1997

4.  Inhaled nitrous oxide (Entonox) as a short acting sedative during bone marrow examination.

Authors:  B Steedman; J Watson; S Ali; M L Shields; R D Patmore; D J Allsup
Journal:  Clin Lab Haematol       Date:  2006-10

5.  Bone marrow trephine biopsy.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

6.  Use of combined oral narcotic and benzodiazepine for control of pain associated with bone marrow examination.

Authors:  T J Dunlop; C Deen; S Lind; R J Voyle; J G Prichard
Journal:  South Med J       Date:  1999-05       Impact factor: 0.954

7.  Morbidity and mortality of deep sedation in outpatient bone marrow biopsy.

Authors:  Christopher M Burkle; Barry A Harrison; Lisa F Koenig; Paul A Decker; David O Warner; Dennis A Gastineau
Journal:  Am J Hematol       Date:  2004-11       Impact factor: 10.047

8.  Premedication with lorazepam before bone marrow biopsy.

Authors:  D W Milligan; M R Howard; A Judd
Journal:  J Clin Pathol       Date:  1987-06       Impact factor: 3.411

9.  Pain during bone marrow aspiration: prevalence and prevention.

Authors:  Philine Vanhelleputte; Kristel Nijs; Michel Delforge; Georges Evers; Steven Vanderschueren
Journal:  J Pain Symptom Manage       Date:  2003-09       Impact factor: 3.612

10.  Entonox as a sedative for bone marrow aspiration and biopsy.

Authors:  E J Gudgin; M W Besser; J I O Craig
Journal:  Int J Lab Hematol       Date:  2008-02       Impact factor: 2.877

  10 in total
  5 in total

1.  A randomized double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography.

Authors:  Thierry N Boellaard; Marije P van der Paardt; Susanne Eberl; Markus W Hollmann; Jaap Stoker
Journal:  BMC Gastroenterol       Date:  2011-11-23       Impact factor: 3.067

2.  Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial.

Authors:  Claudio Cerchione; Giovanni Martinelli; Marco Picardi; Novella Pugliese; Davide Nappi; Aniello Casoria; Angela Gravetti; Delia Cangini; Maria Benedetta Giannini; Sonia Ronconi; Giorgia Simonetti; Andrea Ghelli Luserna Di Rorà; Ugo De Giorgi; Mattia Altini; Sara Bravaccini; Ilaria Santoriello; Cristiano Minucci; Fabrizio Pane; Vincenzo Martinelli
Journal:  J Clin Med       Date:  2020-02-01       Impact factor: 4.241

3.  A Pilot Study on the Addition of Tramadol or Eutectic Mixture of Local Anesthetics (Prilocaine Plus Lignocaine) to Local Lignocaine Infiltration for Prevention of Bone Marrow Aspiration/Biopsy Associated Pain.

Authors:  A H Rudresha; Bipinesh Sansar; D Lokanath; Linu Abraham Jacob; M C Suresh Babu; K N Lokesh; Smitha C Saldanha; Shina Goyal; L K Rajeev
Journal:  South Asian J Cancer       Date:  2021-11-11

4.  A multi-centre randomised double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography.

Authors:  Thierry N Boellaard; Marije P van der Paardt; Markus W Hollmann; Susanne Eberl; Jan Peringa; Lex J Schouten; Giedre Kavaliauskiene; Jurgen H Runge; Jeroen A W Tielbeek; Jaap Stoker
Journal:  BMC Gastroenterol       Date:  2013-05-25       Impact factor: 3.067

Review 5.  Strategies of pain reduction during the bone marrow biopsy.

Authors:  Nikolaj Hjortholm; Emil Jaddini; Kazimierz Hałaburda; Emilian Snarski
Journal:  Ann Hematol       Date:  2012-12-06       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.